Ajanta Pharma Ltd Financials
Company Logo

Ajanta Pharma Ltd Financial Statement

Ajanta Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue1105.64
Operating Expense761.44
Net Profit236.03
Net Profit Margin21.35
Earning Per Share18.77
EBIDTA341.09
Effective Tax Rate20.75

Ajanta Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual3,971.12
Operating Expenses Annual2,851.69
Operating Profit Annual1,235.91
Interest Annual6.80
Depreciation128.28
Net Profit Annual807.24
Tax Annual289.71

Ajanta Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning268.85
Cash Flow from Operations735.35
Cash Flow from Investing105.02
Cash Flow from Financing-1,047.70
Cash Flow at the End61.52

Ajanta Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)31.12
PBIT Margin (%)27.79
PBT Margin (%)23.70
Net PROFIT Margin (%)20.33
Return On Networth / Equity (%)24.24
Return On Networth /Employed (%)32.49
Return On Assets (%)23.78
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.17

Ajanta Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,464.89
Total Current Assets Annual2,441.67
Non Current Assets Annual1,775.77
Total Shareholders Funds Annual3,413.57
Total Assets Annual4,217.44

Ajanta Pharma Ltd Earning Calls

EPS (INR)

Expected

19.61

Reported

19.54

Surprise

-0.36%

Mar 2024

EPS beaten by -0.36%

Dec 2023

EPS beaten by 0.37%

Sep 2023

EPS beaten by 0.36%

Get Your FAQs Right

As of Oct 10, 2024, Ajanta Pharma Ltd has a market capitalization of 28,181.41 Cr. Value Research classifies it as a Large-Cap company.
Yes, Ajanta Pharma Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Ajanta Pharma Ltd recorded a total revenue of approximately 3,971.12 Cr marking a significant milestone in the company's financial performance.
Ajanta Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.1% annually, respectively..
Ajanta Pharma Ltd's current PE ratio is 34.91.
Ajanta Pharma Ltd's ROCE averaged 27.3% from the FY ending March 2022 to 2024, with a median of 28.5%. It peaked at 32.0% in March 2024, reflecting strong capital efficiency over the period..
Ajanta Pharma Ltd's latest EBIT is Rs. 1,103.75 Cr, surpassing the average EBIT of Rs. 906.16 Cr over the 5 years..